{Reference Type}: Journal Article
{Title}: Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll-HD Study.
{Author}: Ogilvie AC;Schultz JL;
{Journal}: Mov Disord Clin Pract
{Volume}: 10
{Issue}: 7
{Year}: 2023 Jul
{Factor}: 4.514
{DOI}: 10.1002/mdc3.13763
{Abstract}: <B>UNASSIGNED: </B>Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist that is used to treat moderate to severe Alzheimer's Dementia (AD) and has been speculated to provide clinical benefits in Huntington's disease (HD).<BR><B>UNASSIGNED: </B>To assess the effectiveness of memantine on the trajectory of cognitive decline in individuals with manifest HD.<BR><B>UNASSIGNED: </B>Using participants from the Enroll-HD study, the primary analysis compared trajectories in cognition over a 5-year period using linear mixed effect models of prevalent and incident memantine users who were propensity-score-matched with non-users on measures of disease progression and demographics.<BR><B>UNASSIGNED: </B>In the primary analysis there were no significant differences in the trajectories between memantine users and non-users on any primary outcomes of interest.<BR><B>UNASSIGNED: </B>Memantine use was not associated with any clinical benefit for individuals with manifest HD. Further studies are warranted to assess the impact of memantine on clinical outcomes in HD.